207 related articles for article (PubMed ID: 1555482)
1. Bolus thrombolysis in venous thromboembolism.
Agnelli G; Parise P
Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
[TBL] [Abstract][Full Text] [Related]
2. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
3. Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1991 Nov; 66(5):592-7. PubMed ID: 1839474
[TBL] [Abstract][Full Text] [Related]
4. Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Blood; 1990 Nov; 76(10):2030-6. PubMed ID: 2122919
[TBL] [Abstract][Full Text] [Related]
5. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
6. Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Spriggs D; Gold HK; Hashimoto Y; Van Houtte E; Vermylen J; Collen D
Thromb Haemost; 1989 Feb; 61(1):93-6. PubMed ID: 2501892
[TBL] [Abstract][Full Text] [Related]
7. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
8. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
9. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
10. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J
Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854
[TBL] [Abstract][Full Text] [Related]
11. Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
Zeymer U; von Essen R; Tebbe U; Niederer W; Mäurer W; Vogt A; Neuhaus KL
Am J Cardiol; 1995 Nov; 76(14):997-1001. PubMed ID: 7484879
[TBL] [Abstract][Full Text] [Related]
12. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
13. Reocclusion after thrombolysis: a problem solved by hirudin?
Rübsamen K; Eschenfelder V
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):97-100. PubMed ID: 1773004
[TBL] [Abstract][Full Text] [Related]
14. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
15. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
[TBL] [Abstract][Full Text] [Related]
16. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
Diehl JL; Meyer G; Igual J; Collignon MA; Giselbrecht M; Even P; Sors H
Am J Cardiol; 1992 Dec; 70(18):1477-80. PubMed ID: 1442621
[TBL] [Abstract][Full Text] [Related]
18. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M
Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132
[TBL] [Abstract][Full Text] [Related]
19. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
20. [rt-PA in extracardiac thromboembolic vascular occlusions].
Cortellaro M; Cofrancesco E; Polli EE
Ann Ital Med Int; 1990; 5(1):61-9. PubMed ID: 2119673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
